CD20-directed therapy in autoimmune diseases involving the skin: Role of rituximab

Expert Review of Dermatology

Volumn 3, Issue 3, 2008, Pages 259-278

  Schmidt, Enno ^a   Goebeler, Matthias ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Autoantibody; B lymphocyte; Dermatomyositis; Epidermolysis bullosa acquisita; Lupus erythematosus; Pemphigus; Rituximab; Treatment

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CD19 ANTIGEN; CD20 ANTIGEN; CLEMASTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; DEXAMETHASONE; FC RECEPTOR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PLACEBO; PREDNISOLONE; PROTEIN A; RINGER SOLUTION; RITUXIMAB; SODIUM CHLORIDE;

ABSCESS; ANTIGEN EXPRESSION; AUTOIMMUNE SKIN DISEASE; B LYMPHOCYTE; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BLISTER; BRAIN VASCULITIS; BULLOUS PEMPHIGOID; CARDITIS; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOPENIA; DEEP VEIN THROMBOSIS; DERMATOMYOSITIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; ENDOCARDITIS; EPIDERMOLYSIS BULLOSA ACQUISITA; FEVER; GRAND MAL SEIZURE; HEADACHE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; HYPERSENSITIVITY REACTION; HYPONATREMIA; HYPOTENSION; IMMUNOADSORPTION; INFORMED CONSENT; LUNG EMBOLISM; LYMPHOCYTE DEPLETION; MUCORMYCOSIS; NECROTIZING FASCIITIS; NEUTROPENIA; NONHUMAN; OFF LABEL DRUG USE; PANCYTOPENIA; PARANEOPLASTIC PEMPHIGUS; PATIENT SELECTION; PEMPHIGOID; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; REVIEW; SEIZURE; SEPSIS; SEPTICEMIA; SERUM SICKNESS; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

EID: 55249118180     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.3.259     Document Type: Review

References (135)

1. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84(8), 2457-2466 (1994).
2. Martin P, Furman RR, Coleman M, Leonard JP. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clin. Cancer Res. 13(18 Pt 2), 5636s-5642s (2007).
3. Saleh MN, Gutheil J, Moore M et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin. Oncol. 27(6 Suppl. 12), 99-103 (2000).
4. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6(5), 394-403 (2006).
5. Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol. Int. 28(3), 205-215 (2008).
6. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50(8), 2580-2589 (2004).
7. Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label Phase II study. Arthritis Rheum. 52(9), 2740-2750 (2005).
8. Tanaka Y, Yamamoto K, Takeuchi T et al. A multicenter Phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol. 17(3), 191-197 (2007).
9. Schollkopf C, Kjeldsen L, Bjerrum OW et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk. Lymphoma 47(2), 253-260 (2006).
10. De Vita S, Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun. Rev. 5(7), 443-448 (2006).
11. Edwards JC, Cambridge G, Leandro MJ B cell depletion therapy in rheumatic disease. Best Pract. Res. Clin. Rheumatol. 20(5), 915-928 (2006).
12. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5(7), 564-576 (2006).
13. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24(13), 2121-2143 (2005).
14. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 48(2), 125-132 (1998).
15. Vugmeyster Y, Howell K. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int. Immunopharmacol. 4(8), 1117-1124 (2004).
16. Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174(2), 817-826 (2005).
17. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54(2), 613-620 (2006).
18. Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50(11), 3580-3590 (2004).
19. Anolik JH, Campbell D, Felgar RE et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48(2), 455-459(2003).
20. Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. 139(3), 439-446 (2005).
21. Schmidt E, Benoit S, Brocker EB, Zillikens D, Goebeler M. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch. Dermatol. 142(2), 147-150 (2006).
22. Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. N. Engl. J. Med. 357(6), 545-552 (2007).
23. Goebeler M, Herzog S, Brucker EB, Zillikens D. Rapid response of treatmentresistant pemphigus foliaceus to the antiCD20 antibody rituximab. Br. J. Dermatol. 149(4), 899-901 (2003).
24. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004).
25. Cambridge G, Leandro MJ, Teodorescu M et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 54(11), 3612-3622 (2006).
26. Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp. Dermatol. 14(12), 861-875 (2005).
27. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 8(3), R83 (2006).
28. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat. Clin. Pract. Rheumatol. 3(2), 86-95 (2007).
29. Herd M, Zillikens D, Borradori L et al. Recommendations for the use of rituximab (and-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J. Dtsch. Dermatol Ges. 6(5), 366-373 (2008).
30. Anhalt GJ. Paraneoplastic pemphigus. J. Investig. Dermatol. Symp. Proc. 9(1), 29-33 (2004).
31. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scaldedskin syndrome. N. Engl. J. Med. 355(17), 1800-1810 (2006).
32. Goebeler, M Zillikens D. Bullous pemphigoid: diagnosis and management. Expert Rev. Dermatol. 1, 401-411 (2006).
33. Benoit S, Bröcker EB, Schmidt E. Current treatment of pemphigus. G. Ital. Dermatol. Venereol. 142, 363-380 (2007).
34. Schmidt E, Hunzelmann N, Zillikens D, Brocker EB, Goebeler M. Rituximab in refractory autnimmune bullous diseases. Clin. Exp. Dermatol. 31(4), 503-508 (2006).
35. Schmidt E, Brocker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin. Rev. Allergy Immunol. 34(1), 56-64 (2008).
36. Chee R, Nagendran V, Bansal A, Casie Cherry SN, Harland C. B-cell targeted therapy alone may not be effective in bullous pemphigoid. Clin. Exp. Dermatol. 32(1), 111-112 (2007).
37. Connelly EA, Aber C, Kleiner G, Nousari C, Charles C, Schachner LA. Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment. Pediatr. Dermatol. 24(2), 172-176 (2007).
38. Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br. J. Dermatol. 156(1), 194-196 (2007).
39. Hoque SR, Black MM, Cliff S. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy. Clin. Exp. Dermatol. 32(2), 172-175 (2007).
40. Mercader P, Rodenas JM, Pena A, Mascaro JM Jr. Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita. J Eur. Acad. Dermatol. Venereol. 21(8), 1141-1142 (2007).
41. Taintor AR, Leiferman, KM, Hashimoto T, Ishii N, Zone JJ, Hull CM. A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia. J. Am. Acad. Dermatol. 56(5 Suppl.), S73-S76 (2007).
42. Cummins DL, Mimouni D, Tin J, Owens N, Anhalt GJ, Meyerle JH. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J. Am. Acad. Dermatol. 56(1), 153-159 (2007).
43. Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology 214(4), 310-318 (2007).
44. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch. Dermatol. 143(8), 1033-1038 (2007).
45. Niedermeier A, Eming R, Pfutze M et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (antiCD20 monoclonal antibodies). Arch. Dermatol. 143(2), 192-198 (2007).
46. Sadler E, Schafleitner B, Lanschuetzer C et al. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br. J. Dermatol. 157(2), 417-419 (2007).
47. Wallet-Faber N, Franck N, Batteux F et al. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology 215(3), 252-255 (2007).
48. Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J. Dermatolog. Treat. 18(5), 312-314 (2007).
49. Antonucci A, Negosanti M, Tabanelli M, Varotti C. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J. Dermatolog. Treat. 18 (3), 178-183 (2007).
50. Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br. J. Dermatol. 156(5), 990-996 (2007).
51. Mamelak AJ, Eid MP, Cohen BA, Anhalt GJ. Rituximab therapy in severe juvenile pemphigus vulgaris. Cutis 80(4), 335-340 (2007).
52. Muhlhoff C, Megahed M. [Treatment of therapy-resistant pemphigus vulgaris with rituximab and immunoglobulins]. Hautarzt 58(11), 924-926 (2007).
53. Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin. Exp. Dermatol. 33(2), 154-155 (2008).
54. Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, Fernandez-Pugnaire M, Ortego-Centeno N. Lateonset neutropenia following rituximab treatment in patients with autoimmune diseases. Br.J. Dermatol. 157(6), 1271-1273 (2007).
55. Taverna JA, Lerner A, Bhawan J et al. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J. Drugs Dermatol. 6(7), 731-732 (2007).
56. Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br. J. Dermatol. 158(2), 382-388 (2008).
57. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rbeum. 46 (10), 2673-2677 (2002).
58. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br. J. Dermatol. 156(2), 352-356 (2007).
59. Ahmed AR, Spigelman Z, Cavacini LA. Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355(17), 1772-1779 (2006).
60. Schmidt E, Klinker E, Opitz A et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br. J. Dermatol. 148(6), 1222-1229 (2003).
61. Shimanovich I, Herzog S, Schmidt E et al. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin. Exp. Dermatol. 31(6), 768-774 (2006).
62. Kong HH, Prorse NS, Ware RE, Hall RP, 3rd. Successful treatment of refractory childhood pemphgus vulgaris with antiCD20 monoclonal antibody (rituximab). Pediatr. Dermatol. 22 (5), 461-464 (2005).
63. Belgi AS, Azeez M, Hoyle C, Williams RE. Response of pemphigus vulgaris to antiCD20 antibody therapy (rituximab) may be delayed. Clin. Exp. Dermatol. 31(1), 143 (2006).
64. Esposito M, Capriotti E, Giunta A, Bianchi L, Chimenti S. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm. Venereol. 86(1), 87-89 (2006).
65. Barnadas M, Roe E, Brunet S et al. Therapy of paraneoplastic pemphigus with rituximab: a case report and review of literature. J. Eur. Acad. Dermatol. Venereol. 20(1), 69-74 (2006).
66. + follicular lymphoma-associated paraneoplastic pemphigus. Arch. Dermatol. 137(3), 269-272 (2001).
67. Niedermeier A, Worl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur. J. Dermatol. 16 (3), 266-270 (2006).
68. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J. Am. Acad. Dermatol. 45(5), 679-690 (2001).
69. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch. Dermatol. 132(2), 203-212 (1996).
70. Borel C, Launay F, Garrouste C et al. [Rituximab induced remission of pemphigus vulgaris: 2 cases]. Rev. Med. Interne. 28(4), 266-268 (2007).
71. Dupuy A, Viguier M, Bedane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch. Dermatol. 140(1), 91-96 (2004).
72. McGinness JL, Bivens MM, Greer KE, Patterson JW, Saulsbury FT. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J. Am. Acad. Dermatol. 55(1), 143-148 (2006).
73. Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 30(5), 327-329 (2002).
74. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch. Dermatol. 138(3), 380-384 (2002).
75. Schmidt E, Herzog S, Brocker EB, Zillikens D, Goebeler M. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br. J. Dermatol. 153(2), 449-451 (2005).
76. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25(11), 1271-1277 (1982).
77. Petschner F, Walker UA, Schmitt-Graff A, Uhl M, Peter HH. ["Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/ rutuximab]. Dtsch. Med. Wochenschr. 126(37), 998-1001 (2001).
78. Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K. B-cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch. Dis. Child. 93(5), 401-406 (2007).
79. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 206(5), 519-527 (2002).
80. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44(12), 1542-1545 (2005).
81. Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64(6), 913-920 (2005).
82. Marks SD, Patey S, Brogan PA et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 52(10), 3168-3174 (2005).
83. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-rcgulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52(2), 501-513 (2005).
84. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54(9), 2970-2982 (2006).
85. Vallerskog T, Heimburger M, Gunnarsson I et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 8(6), R167 (2006).
86. Uthman I, Taber A, Abbas O, Menassa J, Ghosn S. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology 216(3), 257-259 (2008).
87. Tokunaga M, Saito K, Kawabata D et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. 66(4), 470-475 (2007).
88. Willems M, Haddad E, Niaudet P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J. Pediatr. 148(5), 623-627 (2006).
89. Risselada AP, Kallenberg CG. Therapy-resistent lupus skin disease successfully treated with rituximab. Rheumatology (Oxford) 45(7), 915-916 (2006).
90. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56(4), 1263-1272 (2007).
91. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis. 66(9), 1259-1262 (2007).
92. Chehab G, Sander O, Fischer-Betz R, Schneider M. [Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus]. Z. Rbeumatol. 66(4), 328, 330-326 (2007).
93. Jonsdottir T, Gunnarsson I, Risselada A, Welin Henriksson E, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann. Rheum. Dis. 67(3), 330-334 (2007).
94. Nwobi O, Abitbol CL, Chandar J, Secherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr. Nephrol. 23(3), 413-419 (2008).
95. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 32(9), 1107-1118 (1989).
96. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 362(9388), 971-982 (2003).
97. Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250), 96-100 (2001).
98. Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J. Am. Acad. Dermatol. 56(1), 148-153 (2007).
99. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J. Clin. Rheumatol. 11(5), 264-266 (2005).
100. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 52(2), 601-607 (2005).
101. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann. Rheum. Dis. 65(7), 974-975 (2006).
102. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J. Rheumatol. 33(5), 1021-1026 (2006).
103. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch. Dermatol. 143(6), 763-767 (2007).
104. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 56(9), 3107-3111 (2007).
105. Wollheim FA. Is rituximab a potential new therapy in systemic sclerosis?: new evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin. J. Clin. Rheumatol. 10(3), 155 (2004).
106. Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch. Dermatol. 136(2), 174-178 (2000).
107. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br. J. Dermatol. 153(3), 620-625 (2005).
108. Ioannou Y, Lambrianides A, Cambridge G, Leandro MJ, Edwards JC, Isenberg DA. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann. Rheum. Dis. 67(3), 425-426 (2008).
109. Espana A, Fernandez-Galar M, Lloret P, Sanchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J. Am. Acad. Dermatol. 50(6), 974-976 (2004).
110. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85(8), 894-895 (2000).
111. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N. Engl. J. Med. 345(13), 1000 (2001).
112. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal antiCD20 antibody (rituximab). J. Am. Acad. Dermatol. 51(5), 817-819 (2004).
113. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 56(7), 2116-2128 (2007).
114. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 56(8), 2715-2718 (2007).
115. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath ME Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel Dis. 13(11), 1365-1368 (2007).
116. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J. Drugs Dermatol. 2(5), 564-567 (2003).
117. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358(9292), 1511-1513 (2001).
118. Zecca M, Nobili B, Ramenghi U et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 10l(10), 3857-3861 (2003).
119. Bennett CM, Rogers ZR, Kinnamon DD et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107(7), 2639-2642 (2006).
120. Vugmeyster Y, Beyer J, Howell K et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J. Immunother. 28(3), 212-219 (2005).
121. Shan D, Press OW, Tsu TT, Hayden MS, Ledbetter JA. Characterization of scFv-lg constructs generated from the and-CD20 mAb 1F5 using linker peptides of varying lengths. J. Immunol. 162(11), 6589-6595 (1999).
122. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104(6), 1793-1800 (2004).
123. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8(3), R74 (2006).
124. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2(11), 619-626 (2006).
125. Erre GL, Pardini S, Faedda R, Passiu. G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 17(1), 50-55 (2008).
126. Walsh M, Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int. 72(6), 676-682 (2007).
127. De Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig. Liver Dis. 39(Suppl. 1), S122-S128 (2007).
128. D'Arena G, Califano C, Annunziata M et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur. J. Haematol. 79(1), 53-58 (2007).
129. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit. Rev. Oncol. Hematol. 63(1), 47-52 (2007).
130. Zivkovic SA. Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy. Expert Rev. Neurother. 6(9), 1267-1274 (2006).
131. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J. Rheumatol. 34(9), 1864-1868 (2007).
132. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358(7), 676-688 (2008).
133. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J. Neurol. 254(7), 968-969 (2007).
134. Zaja F, Bacigalupo A, Patriarca. F et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 40(3), 273-277 (2007).
135. Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J. Allergy Clin. Immunol. 121(1), 122-128 (2008).